BioCentury | May 17, 2019
Clinical News

AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

...data from an abstract released ahead of this year's ASCO meeting showed that telisotuzumab vedotin (ABBV-399...
...receptor; PD-1 (PDCD1; CD279) - Programmed cell death 1 Brian Moy, Assistant Editor depatuxizumab mafodotin (abt-414) telisotuzumab vedotin (ABBV-399) AbbVie...
BioCentury | Jun 6, 2016
Clinical News

ABBV-399: Phase Ib data

...lung cancer (NSCLC) in an open-label, dose-escalation, U.S. and French Phase I/Ib trial showed that ABBV-399...
...response ranging from 1-5 months. There were no responses among 9 patients with c-MET-negative NSCLC. ABBV-399...
...the American Society of Clinical Oncology meeting in Chicago. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABBV-399...
Items per page:
1 - 2 of 2